Biotech | February 13, 2021
Biocon Biologics and Viatris receive European Commission approval for Kixelle, Biosimilar Insulin Aspart
The centralized marketing authorization granted by the EC is valid in all EU Member
The centralized marketing authorization granted by the EC is valid in all EU Member
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
